Cite
HARVARD Citation
Haddad, R. et al. (2023). Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. Journal of clinical oncology. 41 (12), pp. 2166-2180. [Online].